Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX87 + HLX22 or pertuzumab vs TCbHP in HER2-positive early/locally advanced breast cancer (neoadjuvant)
CTR20254887Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gq1005, hlx22, pertuzumab in breast cancer, sponsored by HyBioPharma. Started Dec 2025; status: active.
02
Drugs
gq1005hlx22pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254887.